Literature DB >> 3157586

Effect of the dopamine D-1 antagonist SCH 23390 on rotational behaviour induced by apomorphine and pergolide in 6-hydroxy-dopamine denervated rats.

M Herrera-Marschitz, U Ungerstedt.   

Abstract

The experiments concerned the effects of the D-1 dopamine antagonist SCH 23390 on the rotational behaviour induced by apomorphine and pergolide in 6-hydroxy-dopamine denervated rats. SCH 23390 dose dependently inhibited the rotational behaviour induced by apomorphine. A significant inhibitory effect was obtained after 0.05 mg/kg s.c. of SCH 23390, which involved a change of the typical two-peak pattern of rotation induced by apomorphine. While the first peak of rotation was not significantly modified, the last peak of rotation induced by apomorphine was inhibited in a dose-dependent manner. No significant inhibition of the total rotation induced by pergolide was observed after SCH 23390 pretreatment. SCH 23390 seemed to enhance the duration of the rotation induced by pergolide, resulting in an increase in the total number of turns. However, the intensity of the maximal peak of rotation induced by pergolide was significantly inhibited after 5.0 mg/kg s.c. of SCH 23390. Comparison of the potency with which SCH 23390 inhibited the apomorphine- and pergolide-induced maximal peaks of rotation reveals that SCH 23390 was approximately 100 times more potent in inhibiting the apomorphine than the pergolide response. The results, compared with those in our previous report, show that the D-2 dopamine antagonist sulpiride was 1000 times more potent in inhibiting the pergolide than the apomorphine rotation. The present results support the hypothesis that apomorphine and pergolide induce rotation in 6-hydroxy-dopamine denervated rats by differential actions on D-1 and D-2 receptor sites.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3157586     DOI: 10.1016/0014-2999(85)90395-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

1.  Apomorphine response plasticity in lesioned rats: supersensitivity dependency and lack of drug- or non-drug-associated environmental cuing.

Authors:  D M Coward
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

2.  Neurocircuitry of the basal ganglia studied by monitoring neurotransmitter release. Effects of intracerebral and perinatal asphyctic lesions.

Authors:  M Herrera-Marschitz; C F Loidl; Z B You; K Andersson; R Silveira; W T O'Connor; M Goiny
Journal:  Mol Neurobiol       Date:  1994 Aug-Dec       Impact factor: 5.590

3.  Effects of dopamine receptor antagonists on gastrin and vomiting responses to apomorphine.

Authors:  M Goiny; K Uvnäs-Moberg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-07       Impact factor: 3.000

4.  PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride.

Authors:  L Farde; C Halldin; S Stone-Elander; G Sedvall
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

5.  Drug-induced circling preference in rats. Correlation with monoamine levels.

Authors:  S F Ali; K J Kordsmeier; B Gough
Journal:  Mol Neurobiol       Date:  1995 Aug-Dec       Impact factor: 5.590

Review 6.  Exploring neurocircuitries of the basal ganglia by intracerebral administration of selective neurotoxins.

Authors:  Mario Herrera-Marschitz; Diego Bustamante; Paola Morales; Michel Goiny
Journal:  Neurotox Res       Date:  2007-04       Impact factor: 3.911

7.  Inhibition of SKF 38393- and pergolide-induced circling in rats with unilateral 6-OHDA lesion is correlated to dopamine D-1 and D-2 receptor affinities in vitro.

Authors:  J Arnt; J Hyttel
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

8.  New information of dopaminergic agents based on quantum chemistry calculations.

Authors:  Guillermo Goode-Romero; Ulrika Winnberg; Laura Domínguez; Ilich A Ibarra; Rubicelia Vargas; Elisabeth Winnberg; Ana Martínez
Journal:  Sci Rep       Date:  2020-12-09       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.